Elisabeth Chroni

Elisabeth Chroni

Professor of Neurology/ Head of Neurology Dept

Dr Elisabeth Chroni is a Professor of Neurology and Head of Neuromuscular Unit in University Hospital of Patras, Greece. Her main research interests include clinical and neurophysiological aspects of neuromuscular diseases, particularly neuromuscular junction diseases, autoimmune  neuropathies, hereditary myopathies and motor neuron diseases.

She was elected representative of Myasthenia Branch of Hellenic Neurological Society for 2016-17 as well as a representative of Hellenic Neurological Society in peripheral neuropathies and clinical neurophysiology. In addition, she serves on Scientific Panels of European Academy of Neurology for since 2015. She is the head of a committee responsible  for the development of a national registry of ALS patients.

Her teaching experience includes undergraduate course to medical students, postgraduate lessons to neurology trainees, participation in postgraduate structural programs in the Universities of Athens, Greece and Uppsala, Sweden.

She is the author of 152 peer reviewed articles in international journals (total IF 430, Citations 2850). She has been involved 8 international multi-center studies (phase II & III) on neuromuscular diseases as Principal Investigator and as a collaborator in 4 Funded Clinical Trials (1991-1994 in the U.K and 2012-2016 in Greece). She has been invited to present her work at 59 national/international meetings and has chaired 40 national scientific sessions. She has done work as a reviewer in 37 International Scientific Journals / Member of Editorial Board in 3 journals. Finally, she has served as member of organizing committees of 5 national meetings.

Connect
Connect trials
Recruiting
Fase iii

Trial COURAGE-ALS

Industry trial

Grazie alla ricerca COURAGE-ALS esaminiamo gli effetti e la sicurezza del farmaco Reldesemtiv per il trattamento della SLA. Questa sperimentazione è stata commissionata da Cytokinetics.

Continua a leggere
Recruiting
Fase iii

Studio PHOENIX

Industry trial

Amylyx Pharmaceuticals Inc sta conducendo uno studio di fase 3 per determinare la sicurezza e l’efficacia del suo composto “AMX0035” per il trattamento della SLA.

Continua a leggere
Active
Fase iii

Trial ADORE

Industry trial

Ferrer sta conducendo uno studio di fase 3 per valutare la sicurezza e la potenziale efficacia di un farmaco sperimentale per le persone con sclerosi laterale amiotrofica (SLA).

Continua a leggere
Active
Fase ii

Trial APL2-ALS-206

Industry trial

In questa fase 2 della ricerca esaminiamo gli effetti e la sicurezza del farmaco Pegcetacoplan per il trattamento della SLA. Questa sperimentazione è stata commissionata da Apellis Pharmaceuticals.

Continua a leggere
Active
Fase ii

RT001 nella sclerosi laterale amiotrofica

In questo studio clinico di fase 2, studieremo la sicurezza e l’efficacia del composto RT001 in persone affette da SLA. Questo studio clinico è sponsorizzato da Retrotope Inc.

Continua a leggere
Recruiting
Fase iii

TUDCA-SLA

Questo studio clinico intende valutare l’efficacia dell’acido tauroursodesossicolico (TUDCA) come trattamento aggiuntivo per la SLA.

Continua a leggere